High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease
Authors:
- 1 May 1993
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 66 (5) , 251-256
Abstract
Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n=44), autologous BM plus peripheral blood stem cells (PBSC) (n=2), PBSC (n=1), syngeneic (n=1), or allogeneic BM (n=3). All patients had received standard salvage chemotherapy prior to HDT and were classified as sensitive (n=33) or resistant (n=17) to this treatment; one patient was in untreated relapse prior to BMT. The preparative regimens for patients receiving autologous BM and/or PBSC consisted of cyclophosphamide, VP 16, and BCNU (CVB) (n=44) or BCNU, etoposide, ara-C, and melphalan (BEAM) (n=3). The patients receiving allogeneic transplants were treated with the CVB regimen (n=2) or busulfan (16 mg/kg body wt.) and cyclophosphamide (200 mg/kg body wt.). With a median follow-up of 12 months, overall survival for 44 patients grafted with autologous BM is 61%±9%, progression-free survival for patients with sensitive disease is 44%±11%; no patient with resistant relapse survived beyond 1 year post transplant. Two of three patients grafted with allogeneic BM still survive 15 and 24 months after BMT with Karnofsky performance scores of 70% and 100%, respectively. The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving ≥600 mg/m2 of BCNU. Three of these patients have died. The results show that HDT followed by hematopoietic stem cell rescue may effectively salvage an important fraction of patients with relapsed HD who respond to standard chemotherapy. The same approach is largely unsuccessful in patients with proven refractoriness to standard chemotherapy. Whether HDT followed by BMT or PBSC support is superior to intensive chemotherapy without stem cell support can be answered only by a prospectively randomized trial.Keywords
This publication has 34 references indexed in Scilit:
- Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's diseaseBritish Journal of Haematology, 1992
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- The second chance for advanced Hodgkin's disease.Journal of Clinical Oncology, 1992
- Phase II study of moplace chemotherapy for patients with previously treated Hodgkin's disease: A calgb studyMedical and Pediatric Oncology, 1990
- Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.1987
- High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1987
- 3RD-LINE CHEMOTHERAPY FOR RESISTANT HODGKINS-DISEASE WITH LOMUSTINE, ETOPOSIDE, AND METHOTREXATE1987
- Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171.1985
- Combination chemotherapy for the treatment of Hodgkin's disease in relapseCancer Chemotherapy and Pharmacology, 1983
- Evaluation of survival data and two new rank order statistics arising in its consideration.1966